このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

2026年7月15日 更新者:Huan Zhou

A Phase II, Open-Label, Single-Arm Study of JS212 in Combination With JS111 as First-Line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

This is a single-arm clinical study evaluating the safety, tolerability, and preliminary efficacy of JS212 in combination with JS111 as first-line treatment in participants with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy for advanced disease.

The study consists of a safety lead-in stage followed by a clinical expansion stage. Approximately 20 participants are planned to be enrolled across the two stages. Participants will receive JS212 by intravenous infusion on Day 1 of each 21-day cycle and JS111 at 160 mg orally once daily until treatment discontinuation criteria are met.

During the safety lead-in stage, up to 10 participants will be enrolled and monitored for significant toxicities during the first 21 days after initial administration. The Safety Monitoring Committee (SMC) will review available safety, tolerability, and efficacy data and determine the JS212 dose to be further evaluated, whether an additional higher or lower dose should be explored, and whether the study may proceed to the clinical expansion stage.

調査の概要

状態

まだ募集していません

詳細な説明

This is a single-arm clinical study designed to evaluate the safety, tolerability, and preliminary antitumor activity of JS212 in combination with JS111 as first-line treatment in participants with EGFR-mutant locally advanced or metastatic NSCLC who have not previously received systemic therapy for EGFR-mutant advanced disease.

Participants will receive JS212 by intravenous infusion on Day 1 once every 3 weeks (Q3W), in combination with JS111 at 160 mg administered orally once daily (QD). Each treatment cycle is 21 days. Study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined treatment discontinuation criterion is met.

The study includes two sequential stages: a safety lead-in stage and a clinical expansion stage. Approximately 20 participants are planned to be enrolled in total, although the final sample size may be adjusted by the Safety Monitoring Committee based on accumulating safety, tolerability, and efficacy data.

Safety Lead-in Stage

Up to 10 participants will be enrolled in the safety lead-in stage. The first 21 days following the initial administration of JS212 and JS111 will constitute the significant toxicity observation period.

The SMC will review the accumulated data and determine the JS212 dose to be used in combination with JS111 during the clinical expansion stage.

Before study initiation or during study conduct, the SMC may also consider emerging safety, tolerability, pharmacologic, and efficacy data from other ongoing studies of JS212 administered as monotherapy or in combination with other agents. Based on these data, the SMC may recommend modification of the JS212 dose, evaluation of another dose level, or omission of the safety lead-in stage and direct initiation of the clinical expansion stage, as specified in the SMC Charter.

Clinical Expansion Stage

After review of the safety lead-in data, participants enrolled in the clinical expansion stage will receive the SMC-selected dose of JS212 in combination with JS111 at 160 mg QD. The clinical expansion stage will further characterize the safety, tolerability, and preliminary antitumor activity of the combination.

Treatment will be administered in 21-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent, or another protocol-defined treatment discontinuation criterion is met. The study is expected to enroll approximately 20 participants in total across the safety lead-in and clinical expansion stages. The SMC may adjust the number of participants based on emerging study data.

Study Objectives

The primary objective is to evaluate the safety and tolerability of JS212 in combination with JS111 and to determine the JS212 dose to be further evaluated in combination with JS111.

The secondary or exploratory objective is to evaluate the preliminary antitumor activity of JS212 in combination with JS111 as first-line treatment in participants with EGFR-mutant locally advanced or metastatic NSCLC.

研究の種類

介入

入学 (推定)

20

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Anhui
      • Hefei、Anhui、中国、230088
        • The First Affiliated Hospital of Anhui Medical University
        • コンタクト:
          • Hospital
        • コンタクト:
        • 主任研究者:
          • Huan Zhou, Ph.D
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200030
        • Shanghai Chest Hospital
        • コンタクト:
          • Zhiren Yang, Ph.D.
          • 電話番号:086 13965082087
          • メール:503091240@qq.com
        • コンタクト:
          • University
        • 主任研究者:
          • Zhiren Yang, Ph.D

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Participants must meet all of the following criteria to be eligible for enrollment in this study:

    1. Male or female participants aged 18 to 75 years, inclusive, at the time of signing the informed consent form.
    2. Histologically or cytologically confirmed recurrent or metastatic solid tumor that is unresectable and not amenable to curative radiotherapy or chemoradiotherapy.
    3. Confirmed EGFR-sensitizing mutation, defined as an exon 19 deletion or L858R mutation, either occurring alone or together with other EGFR mutations, including concomitant T790M mutation. Local laboratory test reports are acceptable, provided that testing is performed using a well-validated assay, an assay that has passed external quality assessment, a laboratory qualified for molecular pathology diagnosis or genetic testing, or an assay approved by the National Medical Products Administration (NMPA). Participants must not have received prior systemic antitumor therapy for locally advanced or metastatic nonsquamous NSCLC. Participants with recurrent NSCLC who previously received adjuvant or neoadjuvant therapy, including chemotherapy, radiotherapy, or other treatment, or definitive radiotherapy or chemoradiotherapy, may be enrolled if the interval between the last treatment and disease recurrence is more than 6 months.
    4. At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
    5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
    6. Life expectancy of at least 12 weeks.
    7. Adequate major organ function.
    8. Women of childbearing potential (WOCBP) who are sexually active with a nonsterilized male partner must have a negative serum pregnancy test within 7 days before the first dose and must agree to have no plans for pregnancy and to use highly effective contraception from the time of signing the informed consent form until 7 months after the last dose of JS212 or 2 months after the last dose of JS111, whichever contraception period is longer.
    9. Nonsterilized male participants who are sexually active with a female partner of childbearing potential must agree to use effective contraception, as described in Appendix 2, from the time of signing the informed consent form until 4 months after the last dose of JS212 or JS111. Sperm donation is prohibited during this period.
    10. The participant voluntarily agrees to participate in the study and signs the informed consent form.

Exclusion Criteria:

  • Participants meeting any of the following criteria will be excluded from the study:

    1. Any of the following disease-related conditions:

    1. Histologically or cytologically confirmed tumor containing a small-cell lung cancer component, large-cell neuroendocrine carcinoma, sarcomatoid features, or a squamous cell carcinoma component greater than 10%;
    2. Known leptomeningeal metastases;
    3. Symptomatic brain parenchymal metastases. Participants with asymptomatic brain metastases may be enrolled if considered stable by the investigator.
    4. Uncontrolled pleural effusion or pericardial effusion, or ascites requiring repeated drainage once per month or more frequently;
    5. Spinal cord compression not treated with surgery and/or radiotherapy, or previously diagnosed spinal cord compression without clinical evidence of disease stability for at least 4 weeks before enrollment following treatment.

    2. Receipt of any of the following treatments:

    1. Chemotherapy or other systemic antitumor therapy within 3 weeks or 5 half-lives before the first dose, whichever is shorter; small-molecule targeted therapy within 2 weeks before the first dose; or limited-field local radiotherapy, such as palliative radiotherapy for bone metastases, within 2 weeks before the first dose;
    2. Use of a strong CYP3A inhibitor or inducer within 14 days before the first dose of study treatment, or anticipated need for continued treatment with such medications during the study;
    3. Current treatment with medications known to prolong the QT interval or potentially cause torsades de pointes, or anticipated need for continued treatment with such medications during the study;
    4. Receipt of any investigational drug within 4 weeks or 5 half-lives before the first dose of study treatment, whichever is shorter;
    5. Concurrent enrollment in another clinical study, unless it is an observational, noninterventional study or the participant is in the follow-up phase of an interventional clinical study;
    6. Major surgery, such as craniotomy, thoracotomy, or laparotomy, within 4 weeks before the first dose of study treatment;
    7. Prior treatment with any EGFR tyrosine kinase inhibitor, any antibody-drug conjugate with a topoisomerase I inhibitor payload, or any antibody and/or antibody-drug conjugate targeting EGFR and/or HER3;

    3. Toxicities from prior antitumor therapy that have not recovered to Grade 1 or lower according to CTCAE.

    4. Known allergy or hypersensitivity to any study treatment or any of its excipients.

    5. Any of the following cardiac findings:

    1. Fridericia-corrected QT interval (QTcF) at rest of ≥450 milliseconds in male participants or ≥470 milliseconds in female participants, based on the mean of 3 QTcF measurements obtained during screening; 2. Clinically significant arrhythmia, including but not limited to complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, or PR interval >250 milliseconds; 3. Risk factors for torsades de pointes, such as clinically significant hypokalemia as judged by the investigator, a family history of long QT syndrome, or a family history of arrhythmia, such as pre-excitation syndrome; 4. Left ventricular ejection fraction (LVEF) <50%. 6. Any condition that may affect the absorption, distribution, metabolism, or elimination of oral medication, including inability to swallow medication, frequent vomiting, persistent uncontrolled diarrhea, extensive gastrointestinal resection, Crohn's disease, or ulcerative colitis.

    7. Confirmed or suspected interstitial lung disease, drug-induced pneumonitis, a history of idiopathic pneumonitis or idiopathic pulmonary fibrosis, or another moderate or severe pulmonary disease that substantially impairs lung function, except for Grade 1 or lower radiation pneumonitis.

    8. Any severe or uncontrolled ocular disorder, particularly severe dry eye syndrome, keratoconjunctivitis sicca, severe exposure keratitis, or another condition that may increase the risk of epithelial injury, as judged by the physician; or an ocular abnormality requiring surgery or expected to require surgery during the study, except for cataracts not requiring urgent surgery.

    9. Severe infection of CTCAE Grade 3 or higher within 4 weeks before the first dose of study treatmen.

    10. A history of immunodeficiency, including a positive human immunodeficiency virus test, another acquired or congenital immunodeficiency disorder, a history of organ transplantation or allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.

    11. Active tuberculosis infection identified by medical history or computed tomography, a history of active tuberculosis infection within 1 year before enrollment, or a history of active tuberculosis infection more than 1 year before enrollment without adequate standard treatment.

    12. Active hepatitis B, defined as hepatitis B surface antigen (HBsAg) positivity with hepatitis B e antibody (HBeAb) or hepatitis B core antibody (HBcAb) positivity and HBV DNA ≥1000 copies/mL or ≥200 IU/mL; or active hepatitis C, defined as hepatitis C virus antibody positivity with HCV RNA above the lower limit of detection of the assay.

    13. Any other malignancy diagnosed within 5 years before the first dose that required treatment, except for malignancies with a low risk of metastasis and a 5-year survival rate greater than 90%, such as adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, adequately treated localized prostate cancer, or adequately treated papillary thyroid carcinoma.

    14. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study.

    15. Uncontrolled concomitant disease, including but not limited to symptomatic congestive heart failure within 6 months before the first dose of study treatment, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia.

    16. Any other factor that, in the investigator's judgment, may cause the participant to discontinue the study prematurely, including a current or prior medical condition, including psychiatric illness, requiring concomitant treatment; a clinically significant laboratory abnormality; or family or social circumstances that may affect participant safety or the collection of study data.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:JS212注射用 + JS111カプセル (AP-L1898)

JS212:JS212は、21日周期の各サイクルの第1日に静脈内点滴投与されます。

JS111:160 mgを1日1回(QD)

21日サイクルの各1日目に静脈内点滴で投与されます。
160 mg once daily (QD)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
安全性(有害事象)
時間枠:最大6年間
有害事象(AEs)の発生率と重症度、および異常な検査所見または臨床所見。
最大6年間
ORR
時間枠:up to 3 years
Objective response rate (ORR), assessed per RECIST v1.1
up to 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
PFS
時間枠:最長6年間
研究者による評価(RECIST v1.1)に基づく無増悪生存期間(PFS)
最長6年間
DoR
時間枠:最大6年
BICRおよび研究者による評価に基づく奏効期間(DoR)
最大6年
DCR
時間枠:最大6年間
BICRおよび治験責任医師により評価された疾患制御率(DCR)
最大6年間
OS
時間枠:最大6年間
全生存期間(OS)
最大6年間

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年7月13日

一次修了 (推定)

2026年11月13日

研究の完了 (推定)

2029年7月23日

試験登録日

最初に提出

2026年7月15日

QC基準を満たした最初の提出物

2026年7月15日

最初の投稿 (実際)

2026年7月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月20日

QC基準を満たした最後の更新が送信されました

2026年7月15日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • NSCLC-IIT-JS212-F01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する